Evotec is a life science company with a unique business model focused on delivering highly effective new therapeutics to patients. The Company leverages its multimodality platform for proprietary projects and within a network of partners including Pharma, Biotech, academics, and other healthcare stakeholders. With more than 5,000 highly qualified people at 17 sites, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics.
Evotec’s iPSC infrastructure represents one of the largest and most sophisticated platforms in the industry. It has been developed over the last years with the goal to 1) industrialize iPSC-based drug screening in terms of throughput, reproducibility and robustness to reach the highest industrial standards, and to 2) deliver off-the-shelf iPSC-based cell therapy products to patients.